News

ASM Journal Article Highlights RP557 Efficacy in Candidiasis

September 1, 2019

SAN FRANCISCO, CA. – Riptide Bioscience, Inc., announces the publication of a research study demonstrating remarkable efficacy for its drug candidate RP557 in recurrent vaginal fungal infections. The study, entitled “Designed Antimicrobial Peptides for Recurrent Vulvovaginal Candidiasis Treatment,” appears in the August 2019 issue of Antimicrobial Agents and Chemotherapy, a publication of the American Society for Microbiology and the major scholarly journal devoted to antimicrobials (https://aac.asm.org) (doi: 10.1128/AAC.02690-18).

Read more >

Riptide Presents Promising Late Preclinical Results at IPF Summit

August 27, 2019

SAN DIEGO, CA. – Riptide Bioscience President Dr. George Martin today delivered a poster presentation at the 2019 IPF Summit, the largest industry event specifically focused on translational programs in Idiopathic Pulmonary Fibrosis.

Read more >

An Innovative Topical Peptide for the Empirical Treatment of Civilian and Combat Wound Infections

August 19, 2019

SAN FRANCISCO, CA. – Riptide Bioscience, Inc announces that the results of its research on the development of a novel antimicrobial peptide for the treatment of infected wounds have been published in the journal Frontiers in Microbiology.

Read more >

Riptide Addresses International Workshop on Scleroderma Research

July 28, 2019

CAMBRIDGE, UK – Dr. Henry Lopez, Executive Vice President of Riptide Bioscience, today addressed the International Workshop on Scleroderma Research (IWSR). The Workshop, co-sponsored by the University of Pittsburgh and University College London, is the largest international meeting devoted to pathogenic mechanisms in systemic scleroderma (SSc).

Read more >

Riptide Bioscience Announces NCI Contract to Evaluate RP Drug Candidates in Combination with Radiotherapy

October 8, 2018

SAN FRANCISCO, CA. – Riptide Bioscience, Inc., today announced that it has been awarded a $299,000 contract from the National Cancer Institute to evaluate its proprietary drug candidate, RP-185, in combination with radiotherapy.

Read more >

Riptide Bioscience Awarded NIH Grant to Address Diabetic Ulcers

September 19, 2018

SAN FRANCISCO, CA. – Riptide Bioscience, Inc., announced that it has been awarded a $227,000 grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), to develop peptide therapeutics targeting diabetic foot ulcers.

Read more >

 

< Additional articles > Next page